Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2005-03-31
2010-02-23
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S133100, C424S134100, C424S141100
Reexamination Certificate
active
07666418
ABSTRACT:
A recombinant antibody or the antibody fragment thereof which specifically reacts with an extracellular domain of human CCR4; a DNA which encodes the recombinant antibody or the antibody fragment thereof; a method for producing the recombinant antibody or the antibody fragment thereof; a method for immunologically detecting CCR4, a method for immunologically detecting a cell which expressed CCR4 on the cell surface, a method for depleting a cell which expresses CCR4 on the cell surface, and a method for inhibiting production of Th2 cytokine, which comprise using the recombinant antibody according or antibody fragment thereof; a therapeutic or diagnostic agent for Th2-mediated immune diseases; and a therapeutic or diagnostic agent for a blood cancer.
REFERENCES:
patent: 5891996 (1999-04-01), Mateo de Acosta del Rio et al.
patent: 5932703 (1999-08-01), Godiska et al.
patent: 6150132 (2000-11-01), Wells et al.
patent: 6245332 (2001-06-01), Butcher et al.
patent: 6488930 (2002-12-01), Wu et al.
patent: 6498015 (2002-12-01), Godiska et al.
patent: 2002/0019341 (2002-02-01), Butcher et al.
patent: 2002/0160015 (2002-10-01), Wells et al.
patent: 2002/0187930 (2002-12-01), Wells et al.
patent: WO 96/23068 (1996-08-01), None
patent: WO 97/10354 (1997-03-01), None
patent: WO 99/15666 (1999-04-01), None
patent: WO 99/25380 (1999-05-01), None
patent: WO 00/00219 (2000-01-01), None
patent: WO 00/41724 (2000-07-01), None
patent: WO 00/42074 (2000-07-01), None
patent: WO 00/67791 (2000-11-01), None
Wells et al. Inflamm. Res. 1999, 48:353-362.
Chantry et al. Current Drug Targets-Inflammation & Allergy, 2002 1:109-116.
Power et al., “Molecular Cloning and Functional Expression of a Novel CC Chemokine Receptor . . . ”,J. of Biological Chemistry, vol. 270, No. 33 (1995), pp. 19495-19500.
Jones, et al., “Expression pattern to T-cell-associated chemokine receptors and their chemokines correlates with . . . ”,Blood, vol. 96, No. 2 (2000), pp. 685-690.
Mueller, et al., “Enhancement of Antibody-Dependent Cytotoxicity with a Chimeric Anti-GD2/Antibody”,J. of Immunology, vol. 144, No. 4 (1990), pp. 1382-1386.
Riechman, et al., “Reshaping human antibodies for Therapy”,Nature, vol. 332 (1988), pp. 323-327.
van den Berg, et al., “High Expression of the CC Chemokine TARC in Reed-Sternberg Cells”,Am. J. of Pathology, vol. 154, No. 6 (1999), pp. 1685-1691.
D'Ambrosio, et al., “Cutting Edge: Selective Up-Regulation of Chemokine Receptors CCR4 and CCR8 upon Activating of Polarized . . . ”,J. of Immunology, Cutting Edge, 0022-1767/98/502.00, pp. 5111-5115, 1998.
Bonecchi, et al., “Differential Expression of Chemokine Receptors and Chemotactic Responsiveness of Type 1 T Helper . . . ”, J. Exp. Med., vol. 87, No. 1 (1998), pp. 129-134.
Youn et al., “Molecular Cloning and Characterization of a cDNA, CHEMR, Encoding a Chemokine Receptor with . . . ”,Blood, vol. 89, No. 12 (1997), pp. 4448-4460.
Frade, et al., “The Amino-terminal Domain of the CCR2 Chemokine Receptor Acts as Coreceptor for HIV-1 Infection”,J. Clin. Invest., vol. 100, No. 3, (1997), pp. 497-502.
Sims, et al., “A Humanized CD18 Antibody Can Block Function without cell Destruction”,The Journal of Immunology, vol. 151, No. 4 (1993), pp. 2177-2335.
Brams et al., “A humanized anti-human CD154 monoclonal antibody blocks CD154-CD40 mediated human B cell activation”,Int. Immunopharmacol., (2001); vol. 1, pp. 277-294.
Bendig,Methods: A Companion to Methods in Enzymology, vol. 8 (1995), pp. 83-93.
Yoneyama et al.,J. Clin. Invest., vol. 102, No. 11 (1998), pp. 1933-1941.
Suzuki, et al.,Int. Immunol., vol. 11, No. 4 (1999), pp. 553-559.
Imai, et al., “Selective recruitement of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated . . . ”,International Immunology, vol. 11, No. 1 (1999), pp. 81-88.
Andrew, et al.,J. Immunol., vol. 166, No. 1 (2001), pp. 103-111.
Landolfi, et al.,J. Immunol., vol. 166, No. 3 (2001), pp. 1748-1754.
He, et al.,J. Immunol., vol. 160, No. 2 (1998), pp. 1029-1035.
Brown, et al.,Proc. Natl. Acad. Sci. USA, vol. 88, No. 7 (1991), pp. 2663-2667.
Co, et al.,Proc. Natl. Acad. Sci. USA, vol. 88, No. 7 (1991), pp. 2869-2873.
Junghans, et al.,Cancer Res., vol. 50, No. 5 (1990), pp. 1495-1502.
Queen et al,Proc. Natl. Acad. Sci. USA, vol. 86, No. 24, pp. 10029-10033, 1989.
Furuya Akiko
Hanai Nobuo
Nakamura Kazuyasu
Niwa Rinpei
Sakurada Mikiko
Gambel Phillip
Kyowa Hakko Kirin Co., Ltd.
Sughrue & Mion, PLLC
Wen Sharon
LandOfFree
Method for treating Th2-mediated disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating Th2-mediated disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating Th2-mediated disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4183542